Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000545496 | SCV000656935 | likely benign | Pancreatic adenocarcinoma | 2024-01-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024366 | SCV002752832 | uncertain significance | not specified | 2023-10-05 | criteria provided, single submitter | clinical testing | The p.F1012L variant (also known as c.3036T>A), located in coding exon 17 of the PALLD gene, results from a T to A substitution at nucleotide position 3036. The phenylalanine at codon 1012 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |